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Background: Cleft lip and palate (CL/P) is one of the most common malformations in humans. Transforming
growth factor alpha (TGFA) is a well characterized mammalian growth factor which might contribute to the
development of CL/P. This meta-analysis aimed to summarize the association between the TGFA Taq I
polymorphisms and CL/P.
Methods: We retrieved the relevant articles from PubMed, EMBASE, ISI Web of Science and SCOPUS databases.
Studies were selected using specific inclusion and exclusion criteria. The odds ratios (ORs) and their 95% confidence
intervals (95% CIs) were calculated to assess the association between TGFA Taq I polymorphism and CL/P risk.
Meta-analyses were performed on the total data set and separately for the major ethnic groups, disease type and
source of control. All analyses were performed using the Stata software.
Results: Twenty articles were included in the present analysis. There is a significant association between the TGFA
Taq I polymorphism and CL/P (C1C2 vs C1C1: OR = 1.67, 95% CI = 1.23-2.25, C2C2 + C1C2 vs C1C1C1: OR = 1.52,
95% CI = 1.15-2.01; C2 vs C1:OR = 1.41, 95% CI = 1.12-1.78). Stratified analyses suggested that the TGFA Taq I
polymorphism was significantly associated with CL/P in Caucasians (C1C2 vs C1C1: OR = 1.95, 95% CI = 1.34-2.86;
C2C2 + C1C2 vs C1C1: OR = 1.68, 95% CI = 1.18-2.38; C2 vs V1: OR = 1.52, 95% CI = 1.14 -2.02).
Conclusion: TGFA Taq I polymorphism may be associated with the risk of CL/P.
Keywords: Cleft Lip and Palate, Clip lip, Clip palate, Transforming growth factor alpha, Single nucleotide
polymorphism, Meta-analysisBackground
Facial clefting is one of the most common malforma-
tions in humans. Significant differences between popula-
tions in the prevalence of cleft lip or palate (CL/P) have
been reported, with higher rates found in Asians and
American Indians than those observed in Caucasians
and Africans. Palate formation is complex, and there are
numerous potential untoward possibilities, the most
common being delayed shelf horizontalization and inad-
equate shelf growth [1].
Epidemiologic studies suggest that a number of envir-
onmental factors have been examined as risk factors for
CL/P, including maternal smoking, exposure to antiepi-
leptic drugs, antiemetic agents and vitamin use during
the periconceptual period, maternal metabolic factors,* Correspondence: fcjxll@outlook.com
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unless otherwise stated.alcohol consumption and exposure to agricultural che-
micals [2]. Several studies have suggested that maternal
cigarette smoking increased the risk of delivering infants
with orofacial clefts [3-6]. It has previously been shown
that maternal periconceptional intake of multivitamins
containing folic acid decreased the occurrence of CL/P
[6-8]. However, there is a study showing the different
results [9]. A case–control study showed that CL/P was
associated with maternal alcohol consumption [10].
However, Christensen and colleagues found that before
the pregnancy there were fewer case mothers drinking
alcohol than control mothers [11].
The epidemiologic characteristics and risk factors of
CL/P are not clear. There is also a strong genetic com-
ponent to oral clefts. The host susceptibility factors may
play an important role in the development of CL/P.
Ardinger and colleagues performed the first study to use
a case–control design to test candidate genes [12]. Theyd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and two of 12 markers in five genes, with an intronic
Taq1 marker in the transforming growth factor alpha
(TGFA) gene showing the strongest association. TGFA
encoded by a gene mapped at 2p13, is a secretion pro-
tein that binds to the epidermal growth factor receptor
(EGFR) and is situated at the palate epithelium during
palate closing [13]. TGFA may function as a normal embry-
onic version of EGF-related growth factor [14]. EGF/TGFA
and glucocorticoids are believed to regulate the prolifera-
tion and differentiation of palatal epithelial cells both
in vitro and in vivo. Moreover, the continued presence of
EGF inhibits the fusion process; TGFA is likely to have
similar effects. These biological studies suggest that muta-
tions in the TGFA gene might contribute to the develop-
ment of CL/P, especially for those mutations that affect the
timing of the tissue-specific expression of this gene.
The TGFA gene shows a restriction fragment length
polymorphism when treated with Taq I restriction enzyme.
The mutant allele shows a four-base (TAAT) deletion. In
this case, it shows a 178-base pair (bp) C1 allele and a
174-bp C2 allele [15]. TGFA Taq I polymorphism is lo-
cated at intron 5 and has 602 bp in the 59 direction of the
acceptor site of exon 6 [16]. For this polymorphism, C1C1
is wild genotype, C1C2 is heterozygote genotype, and
C2C2 is homozygote mutation genotype. In most studies,
there are different forms of comparisons such as heterozy-
gote comparison (C1C2 vs. C1C1), homozygote compari-
son (C2C2 vs C1C1), dominant model (C1C2 + C2C2 vs
C1C1), recessive model (C2C2 vs C1C2 + C1C1) and al-
lelic model (C2 vs C1). Ardinger and colleagues first
reported association between the Taq I polymorphisms at
the TGFA locus and CL/P susceptibility in a case–control
study [12]. This finding has since been replicated in some
studies [6,15,17-23]. However, there are still controversies
of the effect of TGFA polymorphism on the predisposition
of this malformation [24-35].
The above inconsistent conclusions in the findings of the
studies may be attributed to the size of the samples, the eth-
nic of the sample population and other reasons. In order to
contribute to a better understanding of the role of this gene
in the occurrence of cleft lip, cleft lip, or cleft lip and palate,
we perform an updated meta-analysis on all available case–
control studies, combining data together to reach a larger
sample size, to get more statistical power to evaluate the
association between CL/P susceptibility and TGFA Taq I
polymorphism. Understanding the genetic background and
etiology of CL/P is essential for both the risk assessment and
findings of effective methods for prevention and treatment.
Methods
Data sources
We retrieved the articles using the following terms
“Transforming growth factor alpha or TGFA” and “cleftlip or cleft palate or cleft lip and palate” from PubMed,
Embase, ISI Web of Science and SCOPUS (Last search
was updated on October 2013). There was no any lan-
guage restriction and the age of participants was not
considered as selection criteria. We evaluated potentially
relevant publications by examining their titles and ab-
stracts and all studies matching the eligible criteria were
retrieved.
Study selection and data extraction
Eligible studies were selected according to the following
explicit inclusion criteria: (a) evaluation of the TGFA Taq I
polymorphism and CL/P risks, (b) using the methodology
of a case–control study to keep the homogeneity between
included studies in the meta-analysis.
Duplicate and obviously unrelated articles were elimi-
nated by a single author (C.F.). Abstracts of the remaining
articles were examined independently by two authors (C.F.
and E.Z.) to determine whether the full-text article should
be sought. When there were disagreements between CF
and EZ in selecting papers, the third author (L.L.) would
assess the articles and make the final decision with CF and
EZ. A four-phase flow diagram according to Systematic
Reviews (http://www.prisma-statement.org/) was shown in
Figure 1. We have used the Newcastle-Ottawa Scale
(NOS), suggested by Cochrane Collaboration, for assessing
the quality of each included study in the present meta-
analysis. The following information was obtained from
each publication: first author’s name, publication year,
country origin, ethnicity, case characteristics, total number
of cases and controls, numbers of each group with TGFA
Taq I genotypes, respectively.
Statistical methods
The odds ratios (ORs) and their 95% confidence intervals
(95% CIs) were calculated to assess the association be-
tween TGFA Taq I polymorphism and CL/P. Pooled ORs
were obtained from combination of single study by hetero-
zygote comparison (C1C2 vs. C1C1), homozygote compari-
son (C2C2 vs C1C1), dominant model (C1C2 +C2C2 vs
C1C1), recessive model (C2C2 vs C1C2 +C1C1) and allelic
model (C2 vs C1), respectively. These comparisons were
used to provide more information about the relationship
between the polymorphism and the disease, assess the asso-
ciation in different point of view and validate the associ-
ation by many ways, as well as offer the data for further
study on the gene expression. Meta-analyses were per-
formed on the total data set and separately for the source
of control and disease type. We investigated the between-
study heterogeneity by the Cochran’s Q test and quantified
by I2. To obtain summary statistics for ORs of the
polymorphism and disease, we performed initial analyses
with a fixed-effect model and confirmatory analyses with a
random-effect model if there was significant heterogeneity.
Figure 1 Flow chart of the study selection process.
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effects models produce similar results, and, if not, the
random-effect model usually produces wider CIs than
the fixed-effect model. If the P value is >0.05 of the Q
test, the summary OR estimate of each study was calcu-
lated by the fixed-effect model. Otherwise, the random-
effect model was used.
We assessed potential publication bias by examining
funnel plots and using Egger’s test [36,37]. A funnel plot is
a graph designed to check for the existence of publication
bias in systematic reviews and meta-analyses. In the ab-
sence of publication bias, it assumes that the largest stud-
ies will be plotted near the average, and smaller studies
will be spread evenly on both sides of the average, creating
a roughly funnel-shaped distribution. Deviation from this
shape can indicate publication bias. This approach is very
simple to use but, sometimes, we may have doubts about
the funnel asymmetry, especially if the number of studies
is small. In addition, the funnel may be asymmetric due toa deficient quality of studies or because we are dealing
with interventions whose effect varies with the sample of
each study. For these situations, Egger’s linear regression
could be used. Egger’s test plots the regression line be-
tween precision of the studies (independent variable) and
the standardized effect (dependent variable). When there
isn’t publication bias the regression line originates in the
Y-axis zero. So much further away from zero, further evi-
dence of publication bias. The significance of the intercept
was determined by the t-test as suggested by Egger’s test.
All of P values were two-sided and all analyses were per-
formed using the Stata software version 11.0 (Stata Corp,
College station, TX).
Results
Detailed characteristics of each study are summarized in
Table 1. A total of 20 case–control studies including
3824 cases and 7710 controls contributed to the analysis.
The subjects in the study were population of Caucasian,
Table 1 Characteristics of the studies included in the meta-analysis
Author, year Country Ethnicity Clip type Control characteristics No. (case/control) Case Control
C1C1 C1C2 C2C2 C1/C2 C1C1 C1C2 C2C2 C1/C2
BEATY [31] USA Caucasian CP HB 42/135 - - - 78/6 - - - 248/22
Caucasian CL/P HB 86/135 - - - 163/9 - - - 248/22
African CP HB 13/135 - - - 24/2 - - - 248/22
African CL/P HB 11/135 - - - 22/0 - - - 248/22
TANABE [15] Japan Asian CL/P HB 28/73 - - - 49/7 - - - 129/17
Lilian Jara [21] Chile Hispanic CL/P HB 39/51 33 6 0 72/6 44 6 1 94/8
Sassani [19] USA Caucasian CL/P HB 81/84 54 26 1 134/28 70 13 1 153/15
Asian CL/P HB 6/6 4 2 0 10/2 4 2 0 10/2
African CL/P HB 10/7 4 5 1 13/7 4 3 0 11/3
Ardinger [12] USA Caucasian CL/P HB 78/98 59 17 2 135/21 89 8 1 186/10
Shiang [20] USA Caucasian CP HB 43/170 - - - 69/17 - - - 311/29
Hwang [22] USA Caucasian CP HB 69/284 49 20 0 118/20 239 44 1 522/46
Caucasian CL/P HB 114/284 93 19 2 205/23 239 44 1 522/46
ROMITTI [30] USA Caucasian CP PB 51/295 41 10* - - 235 60* - -
Caucasian CL/P PB 118/295 96 22* - - 235 60* - -
Hecht [24] USA Caucasian CL/P UFM 12/13 11 1 0 23/1 10 2 1 22/4
Chenevix [18] Australia Caucasian CL/P HB 117/113 84 30 3 198/36 94 17 2 205/21
Holder [17] UK Caucasian CL/P HB 60/60 36 14 5 86/24 55 5 0 115/5
CHENEVIX [29] Australia Caucasian CL/P HB 96/100 66 27 3 159/33 90 9 1 189/11
Stoll [25] France Caucasian CL/P HB 98/99 - - - 187/10 - - - 184/14
Caucasian CP HB 57/99 - - - 104/10 - - - 184/14
Christensen [11] Denmark Caucasian CP PB 65/457 49 15 1 113/17 344 102 11 790/124
Caucasian CL/P PB 191/457 145 45 1 335/47 344 102 11 790/124
SHAW [6] USA Caucasian CP PB 114/379 87 27* - - 321 58* - -
Hispanic CP PB 35/175 34 1* - - 164 11* - -
African CP PB 7/20 6 1* - - 18 2* - -
Caucasian CL/P PB 245/379 212 33* - - 321 58* - -
Hispanic CL/P PB 103/175 94 9* - - 164 11* - -
African CL/P PB 12/20 11 1* - - 18 2* - -
Beaty [26] USA Caucasian CP HB 51/87 44 6 1 94/8 79 8 0 166/8
Caucasian CL HB 26/87 21 5 0 47/5 79 8 0 166/8



















Table 1 Characteristics of the studies included in the meta-analysis (Continued)
African CP HB 12/45 10 2 0 22/2 43 2 0 88/2
African CL HB 2/45 2 0 0 4/0 43 2 0 88/2
African CL/P HB 10/45 9 1 0 19/1 43 2 0 88/2
Bertoja [34] Brazil Hispanic CL/P HB 140/142 114 25 1 253/27 121 21 0 263/21
PASSOS-BUENO [32] Brazil Hispanic CL/P HB 536/385 484 51 1 1019/53 344 41 0 729/41
Lidral [28] USA Caucasian CL/P PB 182/251 - - - 327/37 - - - 449/53
Caucasian CP PB 62/251 - - - 109/15 - - - 449/53
Lidral [27] USA Caucasian CL/P PB 652/776 - - - 1204/100 - - - 1436/116
Caucasian CP PB 97/776 - - - 176/18 - - - 1436/116
CL: clip lip, CL/P: clip lip and palate, CP: clip palate, PB: population-based control group, HB: hospital-based control group, UFM: unrelated family members control group.
C1C1, C1C2, C2C2: genotype, C1/C2: allele frequency.



















Table 2 Association between TGFA Taq1 polymorphism and CL/P risk
Model Number of studies Fixed effect Random effect Phet I-squared (%)
C1C2 vs. C1C1 12 1.46 [1.22,1.75] 1.67 [1.23,2.25] 0.009 55.8
C2C2 vs. C1C1 12 1.57 [0.87,2.83] 1.56 [0.78,3.16] 0.525 0.0
C1C2 + C2C2 vs. C1C1 14 1.33 [1.14,1.54] 1.52 [1.15,2.01] 0.000 64.7
C2C2 vs. C1C2 + C1C1 12 1.43 [0.79,2.59] 1.42 [0.70,2.85] 0.634 0.0
C2 vs. C1 18 1.26 [1.12,1.43] 1.41 [1.12,1.78] 0.000 65.2
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including more than one ethnic population. There were
14 studies containing Europeans, 4 studies including
Hispanics, 3 studies involving Africans and 2 studies com-
prising Asians. For the Europeans, Hispanics, Africans
and Asians, sample sizes ranged from 25 to 1525, 90 to
921, 17 to 69 and 12 to 100, respectively. The total
sample size were 2897 cases and 6806 controls for the
Europeans, 853 cases and 753 controls for the Hispanics,
41 cases and 72 controls for the Africans and 33 cases and
79 controls for the Asians. The types of controls included
population-based, hospital-based and unrelated family
members.
NOS results suggested that all of the included studies
are high level quality with the score >6.
Association between the genotypes of TGFA Taq1 and
CL/P risk
A summary of the meta-analysis findings of the associ-
ation between TGFA Taq I and CL/P risk is provided in
Table 2. Meta-analysis showed statistically significantFigure 2 Forest plot of cancer risk associated with TGFA Taq I polymorphassociation between TGFA Taq I polymorphism and
CL/P risk in heterozygote comparison, dominant and
allelic model (C1C2 vs C1C1: OR = 1.67, 95% CI = 1.23-
2.25, P = 0.009 for heterogeneity, I2 = 55.8%; C2C2 +C1C2
vs C1C1: OR = 1.52, 95% CI = 1.15-2.01, P < 0.001 for het-
erogeneity, I2 = 64.7%; C2 vs C1: OR = 1.41, 95% CI = 1.12-
1.78, P < 0.001 for heterogeneity, I2 = 65.2%), but not in the
homozygote and recessive model (C2C2 vs C1C1: OR =
1.57, 95% CI = 0.87-2.83, P = 0.525 for heterogeneity, I2 =
0.0%; C2C2 vs C1C2 +C1C1: OR = 1.43, 95% CI = 0.79-
2.59, P = 0.634 for heterogeneity, I2 = 0.0%). Meta-analysis
results of the association between TGFA Taq I poly-
morphism and CL/P risk under the heterozygote com-
parison model (C1C2 versus C1C1), the dominant
model (C1C2 + C2C2 versus C1C1), and the allelic
model (C2 versus C1) were also shown in Figure 2,
Figure 3 and Figure 4, respectively.
Stratified meta-analysis
Stratified analyses were conducted by ethnicity, source of
control and disease type. Pooled ORs and 95% CIs ofism under the heterozygote comparison model (C1C2 versus C1C1).
Figure 3 Forest plot of cancer risk associated with TGFA Taq I polymorphism under the dominant model (C1C2 + C2C2 versus C1C1).
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group analysis by ethnicity, significantly increased CL/P
risks were found among Caucasian (C1C2 vs C1C1: OR =
1.95, 95% CI = 1.34-2.86; C2C2 + C1C2 vs C1C1: OR =
1.68, 95% CI = 1.18-2.38; C2 vs C1: OR = 1.52, 95% CI =
1.14-2.02). No significantly evaluated risk was foundFigure 4 Forest plot of cancer risk associated with TGFA Taq I polymoamong African and Hispanic population in any of the
genetic models.
In the subgroup analysis according to disease type, the
ORs of the heterozygote comparison, dominant and al-
lelic model with CL/P are statistically significant (C1C2
vs C1C1: OR = 1.60, 95% CI = 1.16-2.20; C2C2 + C1C2 vsrphism under the allelic model (C2 versus C1).
Table 3 Pooled ORs and 95% CIs of stratified meta-analysis
Subgroup Genotype No of
studies
Test of association Test of heterogeneity
OR (95% CI) Z P-value Model P-value I2 (%)
Ethnicity
African
C1C2 + C2C2 vs. C1C1 3 1.92 [0.63,1.90] 1.14 0.253 F 0.754 0.0
C2 vs. C1 3 1.15 [0.50,2.66] 0.33 0.741 F 0.254 26.9
Caucasian
C1C2 vs. C1C1 9 1.95 [1.34,2.86]* 3.48 0.001 R 0.016 57.3
C2C2 vs. C1C1 9 1.50 [0.79,2.84] 1.25 0.211 F 0.341 11.2
C1C2 + C2C2 vs. C1C1 9 1.68 [1.18,2.38]* 2.87 0.004 R 0.000 69.9
C2C2 vs. C1C2 + C1C1 9 1.36 [0.71,2.58] 0.93 0.354 F 0.443 0.0
C2 vs. C1 14 1.52 [1.14,2.02]* 2.87 0.004 R 0.000 74.8
Hispanic
C1C2 vs. C1C1 3 1.02 [0.72,1.43] 0.08 0.935 F 0.594 0.0
C2C2 vs. C1C1 3 1.44 [0.27,7.67] 0.42 0.672 F 0.669 0.0
C1C2 + C2C2 vs. C1C1 4 1.04 [0.76,1.44] 0.27 0.789 F 0.792 0.0
C2C2 vs. C1C2 + C1C1 3 1.40 [0.26,7.46] 0.4 0.692 F 0.663 0.0
C2 vs. C1 3 1.04 [0.75,1.44] 0.23 0.816 F 0.608 0.0
Disease
CP
C1C2 vs. C1C1 3 1.54 [1.04,2.27]* 2.14 0.032 F 0.215 34.9
C2C2 vs. C1C1 3 1.32 [0.35,5.00] 0.40 0.687 F 0.478 0.0
C1C2 + C2C2 vs. C1C1 5 1.45 [1.10,1.91] 2.61 0.009 F 0.281 21.0
C2C2 vs. C1C2 + C1C1 3 1.26 [0.33,4.78] 0.33 0.738 F 0.496 0.0
C2 vs. C1 8 1.38 [1.10,1.73]* 2.82 0.005 F 0.226 25.4
CL/P
C1C2 vs. C1C1 12 1.60 [1.16,2.20]* 2.89 0.004 R 0.010 55.7
C2C2 vs. C1C1 11 1.64 [0.88,3.04] 1.57 0.116 F 0.457 0.0
C1C2 + C2C2 vs. C1C1 11 1.46 [1.09,1.95]* 2.55 0.011 R 0.001 62.7
C2C2 vs. C1C2 + C1C1 11 1.45 [0.82,2.78] 1.25 0.211 F 0.545 0.0
C2 vs. C1 17 1.29 [1.01,1.66]* 2.03 0.042 R 0.000 63.1
Source of control
HB
C1C2 vs. C1C1 10 1.84 [1.32,2.56]* 3.58 0.000 R 0.019 54.7
C2C2 vs. C1C1 10 2.96 [1.35,2.70]* 4.70 0.000 F 0.965 0.0
C1C2 + C2C2 vs. C1C1 10 1.99 [1.35,2.70]* 3.66 0.000 R 0.007 60.1
C2C2 vs. C1C2 + C1C1 10 2.38 [1.06,5.55]* 5.17 0.000 F 0.968 0.0
C2 vs. C1 14 1.63 [1.22,2.18]* 3.28 0.001 R 0.001 63.0
PB
C1C2 + C2C2 vs. C1C1 3 0.99 [0.79,1.24] 0.10 0.917 F 0.549 0.0
C2 vs. C1 3 1.00 [0.83,1.20] 0.02 0.986 F 0.778 0.0
*OR had statistical significance with corresponding 95% CI not including 1. F: Fixed effect model; R: Random effect model.
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95% CI = 1.01-1.66). For the CP, the significant results
were observed in heterozygote comparison, dominant andallelic model (C1C2 vs C1C1: OR = 1.54, 95% CI = 1.04-
2.27; C2C2 + C1C2 vs C1C1: OR = 1.45, 95% CI = 1.10-
1.19; C2 vs C1: OR = 1.38, 95% CI = 1.10-1.73).
Figure 6 Funnel plot under the allelic model (C2 versus C1).
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ORs of the heterozygote comparison, homozygote, domin-
ant, recessive and allelic model for the hospital-based con-
trol are statistically significant (C1C2 vs C1C1: OR = 1.84,
95% CI = 1.32-2.56; C2C2 vs C1C1: OR = 2.96, 95% CI =
1.35-2.70; C2C2 +C1C2 vs C1C1: OR = 1.99, 95% CI =
1.35-2.70; C2C2 vs C1C2 +C1C1: OR = 2.38, 95% CI =
1.06-5.55; C2 vs C1: OR = 1.63, 95% CI = 1.22-2.18).
While, no statistically significant association was found in
population-based controls.
Heterogeneity between studies was observed in overall
comparisons and also subgroup analyses. Thus, meta-
analyses were performed using random-effect models
(Table 2).
To explore potential sources of heterogeneity in this
meta-analysis, meta-regression analyses were implemented.
The covariates included ethnicity and source of control. In
all of the heterozygote comparison, homozygote, dominant,
recessive and allelic models, above potential factors were
probably not the major sources of heterogeneity (P-values
were all >0.05 or near 0.05). The heterogeneity might attri-
bute to other factors, the insufficient data limited to identify
their sources only using meta-regression.
No publication bias was detected by either the inverted
funnel plot or Egger’s test. The shapes of the funnel plots
seemed approximately symmetrical and P values of the
Egger’ tests were not statistical significant (P values were
all >0.05). Figure 5 and Figure 6 showed the funnel plot
under the heterozygote comparison model (C1C2 versus
C1C1) and the allelic model (C2 versus C1).
Discussion
The individual susceptibility plays an important role in
the development of most diseases. Therefore, the studies
of genetic susceptibility are helpful for disease preven-
tion, diagnosis, and treatment.
TGFA is a well characterized mammalian growth factor.
Previous studies found that although TGFA is expressedFigure 5 Funnel plot under the heterozygote comparison
model (C1C2 versus C1C1).in mice during palatogenesis and mice with a null muta-
tion of the TGFA gene have abnormal skin, hair, and eyes,
but they do not have CL/P [38,39]. TGFA is a likely ligand
for epidermal growth factor receptor and newborn epider-
mal growth factor receptor-negative/-negative mice have
high incidence of CL/P which may explain the association
between TGFA polymorphisms and CL/P [40]. In 1989, it
was firstly published that the TGFA Taq I polymorphism
contributed to the development CL/P in humans. From
then on, a growing number of studies have been done to
examine the relationship between TGFATaq I polymorph-
ism and the risks of CL/P. However, the results are not
consistent. In order to better understand the association,
we subjected previously published data to meta-analysis to
evaluate genetic associations between the TGFA Taq I
polymorphism and CL/P susceptibility.
Through this meta-analysis we found that TGFA Taq I
polymorphism increased the risk of CL/P. Mitchell adopted
a reappraisal and showed that there was a statistically
significant association between TGFA and CL/P, However,
there was evidence of significant heterogeneity from dif-
ferent studies, regarding an association between genetic
variation at the TGFA locus and CL/P remains inconclu-
sive [41]. A meta-analysis of gene-environment interaction
showed the suggestive evidence for gene-environment
interaction between the infant’s genotype at the Taq1
marker in TGFA and maternal smoking was limited to CP
[42]. Meta-review of thyroid cancer gene expression profil-
ing studies identifies important diagnostic biomarkers,
including relatively novel or uncharacterized genes such as
TGFA [43]. These results of systematic reviews in some
extent support the findings in the present meta-analysis.
In order to reduce heterogeneity, we performed the
stratified analyses. It is well know that the incidence of
most genetic polymorphisms could vary between differ-
ent ethnic populations and the wide range in TGFA Taq
I allele frequencies across different studies suggests the
heterogeneity between populations may exist [28]. In the
subgroup analysis by ethnicity, we found that TGFA Taq
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http://www.biomedcentral.com/1472-6831/14/88I polymorphism increased the risk of CL/P in Caucasian
population, which agreed with Ardinger and colleagues
[12], Shiang and colleagues [20], Hwang and colleagues
[22], Chenevix-Trench and colleagues [18], Holder and
colleagues [17], and disagreed with Lidral and colleagues
[27], [28], Stoll and colleagues [25] and Christensen and
colleagues [11]. In the subgroup analysis by disease type,
we found the ORs of different disease type were statisti-
cally significant, which suggested disease type was not
mainly result the heterogeneity. In the subgroup analyses
of control characteristics, only the ORs of hospital-based
control groups were statistically significant. Therefore,
subgroup analyses suggested that ethnicity and control
characteristics might contribute to the heterogeneity in
this meta-analysis. The meta-regression analyses suggested
that ethnicity or control characteristics were probably not
the major sources of heterogeneity. The heterogeneity
might attribute to other factors. The insufficient data are
limited to identify the source of heterogeneity only using
meta-regression.
Despite trying our best to perform a comprehensive
meta-analysis, some limitations exist in our study. Al-
though the results for publication bias in our study were
not statistically significant, our analysis used published
international studies, which could arose publication bias.
Lack of the original data of available studies limited our
further evaluation of potential interactions, such as age,
gender, family history, environmental factors and lifestyle.
There were not significant results in stratified analyses
among African and Hispanic population, because there
were too few studies after stratifying. Therefore, more
studies are needed to provide more evidence on the
association between TGFA polymorphism and CL/P in
different ethnic populations.
Although CL/P is a complex disease, our study pro-
vided evidence showing the important role of TGFA
genes polymorphisms in the development of CL/P,
genetic factors determining disease susceptibility and
severity may facilitate personalized medicine. Further
understanding of the interactions between genetic
regulatory mechanisms is critical for discovering new
therapies for managing human CL/P. Specifically, tar-
geted therapy about the polymorphisms of related
genes might be a promising avenue for future CL/P
diagnosis and treatment.
In summary, our meta-analysis supports that the TGFA
Taq I polymorphism is more likely to contribute to the
susceptibility of CL/P, especially in the subgroup of Cauca-
sian population.Conclusion
TGFA Taq I polymorphism may be associated with the
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